pyridoxal-5'-phosphate + ace inhibitor

This is a **combination therapy** of **pyridoxal-5'-phosphate (P5P)**, the active coenzyme form of vitamin B6, with an **angiotensin-converting enzyme (ACE) inhibitor** such as lisinopril, enalapril, or others. P5P acts as a cofactor in many enzymatic reactions, playing a central role in amino acid, glucose, and lipid metabolism, with established effects on improving insulin sensitivity, glycemic control, lipid profile, and vascular function, particularly in individuals with diabetes. ACE inhibitors lower blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, thus relaxing blood vessels and lowering peripheral vascular resistance; they are standard therapies for hypertension and diabetic nephropathy. The **combination of P5P with an ACE inhibitor** has shown synergistic effects in improving endothelial function, vascular health, blood pressure regulation, and reducing diabetic complications such as nephropathy and retinopathy. Phase II clinical studies have tested this combination (for example, P5P 100–1000mg + lisinopril 20mg), especially in hypertensive patients with type 2 diabetes[1][7].

Other names

pyridoxal 5-phosphate + ace inhibitorp5p + ace inhibitorpyridoxal phosphate + ace inhibitorp5p + angiotensin-converting enzyme inhibitor